TARGRETIN™
(bexarotene) MAIN LIFE
HK Reg. No. HK-68294 (04 Jul, 2024)
Composition:1
Targretin™ (bexarotene) is a member of a subclass of retinoids that selectively activate retinoid X receptors (RXRs). Targretin™ is available in capsule form containing 75 mg of bexarotene.
Indication:1
Targretin™ (bexarotene) capsules is indicated for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy.
References
1. TARGRETIN®. HIGHLIGHTS OF PRESCRIBING INFORMATION US 2015. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021055s006lbl.pdf 2. AKEEGA™. Package Insert 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021055s006lbl.pdf 3. LEQEMBI®. HIGHLIGHTS OF PRESCRIBING INFORMATION US 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761269Orig1s001lbl.pdf 4. LITFULO™. HIGHLIGHTS OF PRESCRIBING INFORMATION US 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215830s000lbl.pdf
